グルカゴン様ペプチド（GLP）-1アゴニスト系減量薬の世界市場レポート 2025年

グルカゴン様ペプチド（GLP）-1作動薬の減量薬市場規模は、今後数年間で急成長が見込まれます。2029年には複合年間成長率（CAGR）16.6%で289億1,000万米ドルに成長します。予測期間中の成長は、効果的な減量ソリューションに対する需要の高まり、糖尿病以外の薬剤適応の拡大、研究開発への投資の増加、個別化医療の採用の高まり、消費者向け直接販売による認知度の高まりなどに起因すると考えられます。予測期間における主な動向としては、経口グルカゴン様ペプチド（GLP）-1製剤の開発、徐放性ドラッグデリバリーの進歩、モニタリング用デジタルヘルスツールの統合、創薬・開発における人工知能の活用、有効性を高めるためのペプチド工学の革新などが挙げられます。

肥満の有病率の増加は、グルカゴン様ペプチド（GLP）-1作動薬減量薬市場の拡大を促進すると予想されます。肥満症は、健康上のリスクをもたらす過剰な体脂肪の蓄積によって特徴づけられる病状であり、適切な栄養を欠くファーストフードや糖分の多い飲料の消費の増加など、不健康な食習慣のために一般的になりつつあります。肥満とそれに伴う合併症に罹患する人の数が増え続けるにつれ、効果的な治療オプションに対する需要も高まっています。このため、体重減少をサポートし、代謝の健康を改善する効果が証明されているグルカゴン様ペプチド（GLP）-1作動性減量薬の採用が進んでいます。例えば、2024年3月、世界保健機関（WHO）は、2022年には世界の8人に1人が肥満と共存していると報告しました。25億人の過体重の成人のうち、約8億9,000万人が肥満と分類されました。さらに、世界の成人人口の43％が太りすぎで、16％が肥満とされました。このように、肥満の有病率の増加がGLP-1アゴニスト減量薬市場の成長を促進しています。

GLP-1アゴニスト減量薬市場の主要企業は、肥満治療の有効性を高め、患者の転帰を改善する革新的な治療を導入しています。これらの治療薬はGLP-1ホルモンを模倣して食欲を調節し、満腹感を高め、体重減少を促進します。代謝機能を改善することで、これらの薬剤は長期的な体重管理と肥満抑制をサポートします。例えば、2023年11月、米国の製薬会社イーライリリー・アンド・カンパニーは、肥満や過体重の成人、特に2型糖尿病や睡眠時無呼吸症候群などの関連疾患を持つ成人の慢性的な体重管理を目的とした薬、ゼップバウンドの承認を米国食品医薬品局から取得しました。同薬は、GIPとGLP-1の両ホルモン受容体を活性化することにより、食欲を抑制し、代謝機能を改善します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界のグルカゴン様ペプチド（GLP）-1アゴニスト系減量薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のグルカゴン様ペプチド（GLP）-1アゴニスト系減量薬市場：成長率分析
• 世界のグルカゴン様ペプチド（GLP）-1アゴニスト系減量薬市場の実績：規模と成長、2019年～2024年
• 世界のグルカゴン様ペプチド（GLP）-1アゴニスト系減量薬市場の予測：規模と成長、2024年～2029年、2034年
• 世界のグルカゴン様ペプチド（GLP）-1アゴニスト系減量薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のグルカゴン様ペプチド（GLP）-1アゴニスト系減量薬市場：薬剤別、実績と予測、2019年～2024年、2024年～2029年、2034年
• セマグルチド
• リラグルチド
• チルゼパチド
• その他の薬剤
• 世界のグルカゴン様ペプチド（GLP）-1アゴニスト系減量薬市場：投与経路別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 非経口
• 経口
• 世界のグルカゴン様ペプチド（GLP）-1アゴニスト系減量薬市場：流通チャネル別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 病院薬局
• 小売薬局
• その他の薬局
• 世界のグルカゴン様ペプチド（GLP）-1アゴニスト系減量薬市場、セマグルチドの種類別サブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
• オゼンピック
• ウェゴヴィ
• リュベルスス
• 世界のグルカゴン様ペプチド（GLP）-1アゴニスト系減量薬市場、リラグルチドの種類別サブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
• サクセンダ
• ヴィクトザ
• 世界のグルカゴン様ペプチド（GLP）-1アゴニスト系減量薬市場、チルゼパチドの種類別サブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
• ムンジャロ
• ゼップバウンド
• 世界のグルカゴン様ペプチド（GLP）-1アゴニスト系減量薬市場、その他の薬剤の種類別サブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
• エキセナチド
• デュラグルチド
• アルビグルチド
• エフペグレナチド

第7章 地域別・国別分析

• 世界のグルカゴン様ペプチド（GLP）-1アゴニスト系減量薬市場：地域別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 世界のグルカゴン様ペプチド（GLP）-1アゴニスト系減量薬市場：国別、実績と予測、2019年～2024年、2024年～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• グルカゴン様ペプチド（GLP）-1アゴニスト系減量薬市場：競合情勢
• グルカゴン様ペプチド（GLP）-1アゴニスト系減量薬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc Overview, Products and Services, Strategy and Financial Analysis
  • Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Novo Nordisk A/S
• Teva Pharmaceutical Industries Ltd
• Boehringer Ingelheim
• Jiangsu Hengrui Medicine Co. Ltd
• BioAge Labs
• Hanmi Pharmaceutical
• Innovent Biologics Inc.
• Viking Therapeutics Inc.
• Structure Therapeutics Inc.
• Zealand Pharma A/S
• Regor Therapeutics Inc.
• I-Mab Biopharma（Shanghai）Co. Ltd.
• Altimmune Inc.
• TheracosBio LLC.
• Oramed Pharmaceuticals

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• グルカゴン様ペプチド（GLP）-1アゴニスト系減量薬市場2029年：新たな機会を提供する国
• グルカゴン様ペプチド（GLP）-1アゴニスト系減量薬市場2029年：新たな機会を提供するセグメント
• グルカゴン様ペプチド（GLP）-1アゴニスト系減量薬市場2029年：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Glucagon-like peptide (GLP)-1 agonists are medications that mimic the action of the GLP-1 hormone, helping to regulate blood sugar levels and curb appetite. They promote insulin release, slow gastric emptying, and enhance feelings of satiety. Originally developed for managing type 2 diabetes, these drugs are now widely used for weight management in overweight and obese individuals.

The key drugs in the GLP-1 agonists weight loss market include semaglutide, liraglutide, tirzepatide, and other medications. Semaglutide, branded as Wegovy, is an injectable prescription drug designed to support weight loss in adults with obesity or overweight conditions coupled with weight-related health problems. These medications are available in both parenteral and oral forms and are distributed through hospital pharmacies, retail pharmacies, and other outlets.

The glucagon-like peptide (GLP)-1 agonists weight loss drugs market research report is one of a series of new reports from The Business Research Company that provides glucagon-like peptide (GLP)-1 agonists weight loss drugs market statistics, including glucagon-like peptide (GLP)-1 agonists weight loss drugs industry global market size, regional shares, competitors with a glucagon-like peptide (GLP)-1 agonists weight loss drugs market share, detailed glucagon-like peptide (GLP)-1 agonists weight loss drugs market segments, market trends and opportunities, and any further data you may need to thrive in the glucagon-like peptide (GLP)-1 agonists weight loss drugs industry. The glucagon-like peptide (GLP)-1 agonists weight loss drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The glucagon-like peptide (GLP) -1 agonists weight loss drugs market size has grown rapidly in recent years. It will grow from$13.38 billion in 2024 to $15.63 billion in 2025 at a compound annual growth rate (CAGR) of 16.9%. The growth during the historic period can be attributed to the rising prevalence of obesity, the increasing incidence of type 2 diabetes, greater awareness of obesity-related health risks, higher healthcare spending, a growing focus on chronic disease management, and improved access to healthcare.

The glucagon-like peptide (GLP) -1 agonists weight loss drugs market size is expected to see rapid growth in the next few years. It will grow to$28.91 billion in 2029 at a compound annual growth rate (CAGR) of 16.6%. The growth during the forecast period can be attributed to the growing demand for effective weight loss solutions, the expansion of drug indications beyond diabetes, increased investments in research and development, the rising adoption of personalized medicine, and heightened awareness through direct-to-consumer marketing. Key trends in the forecast period include the development of oral glucagon-like peptide (GLP)-1 formulations, advancements in sustained-release drug delivery, integration of digital health tools for monitoring, the use of artificial intelligence in drug discovery and development, and innovations in peptide engineering to enhance efficacy.

The growing prevalence of obesity is expected to fuel the expansion of the glucagon-like peptide (GLP)-1 agonist weight loss drugs market. Obesity, a medical condition marked by excessive body fat accumulation that poses health risks, is becoming more common due to unhealthy eating habits, such as the increased consumption of fast food and sugary drinks, which lack proper nutrition. As the number of individuals affected by obesity and its associated complications continues to grow, the demand for effective treatment options is also rising. This is driving the adoption of glucagon-like peptide (GLP)-1 agonist weight loss drugs, which have proven efficacy in supporting weight loss and improving metabolic health. For example, in March 2024, the World Health Organization reported that in 2022, one in eight people globally were living with obesity. Among the 2.5 billion overweight adults, approximately 890 million were classified as obese. Furthermore, 43% of the global adult population was overweight, and 16% were considered obese. Thus, the increasing prevalence of obesity is propelling the growth of the GLP-1 agonist weight loss drugs market.

Leading companies in the GLP-1 agonist weight loss drugs market are introducing innovative therapies to improve the efficacy of obesity treatment and enhance patient outcomes. These therapies mimic the GLP-1 hormone to regulate appetite, increase satiety, and promote weight loss. By improving metabolic function, these drugs support long-term weight management and obesity control. For instance, in November 2023, Eli Lilly and Company, a US-based pharmaceutical firm, received approval from the US Food and Drug Administration for Zepbound, a medication designed for chronic weight management in adults with obesity or overweight, especially those with related health conditions such as type 2 diabetes or sleep apnea. The drug works by activating both GIP and GLP-1 hormone receptors to suppress appetite and improve metabolic function.

In December 2023, F. Hoffmann-La Roche AG, a Switzerland-based healthcare company, acquired Carmot Therapeutics for $2.7 billion. This acquisition enables Roche to access Carmot's pipeline of incretin-based therapies for obesity and diabetes, including dual GLP-1/GIP receptor agonists CT-388 and CT-868, as well as GLP-1 receptor agonist CT-996. Carmot Therapeutics, a US-based biotechnology company, specializes in developing disease-modifying therapies for metabolic diseases such as obesity and diabetes.

Major players in the glucagon-like peptide (GLP)-1 agonists weight loss drugs market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc, Amgen Inc., Eli Lilly and Company, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd, Boehringer Ingelheim, Jiangsu Hengrui Medicine Co. Ltd, BioAge Labs, Hanmi Pharmaceutical, Innovent Biologics Inc., Viking Therapeutics Inc., Structure Therapeutics Inc., Zealand Pharma A/S, Regor Therapeutics Inc., I-Mab Biopharma (Shanghai) Co. Ltd., Altimmune Inc., TheracosBio LLC., and Oramed Pharmaceuticals.

North America was the largest region in the glucagon-like peptide (GLP) -1 agonists weight loss drugs market in 2024. The regions covered in glucagon-like peptide (GLP)-1 agonists weight loss drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the glucagon-like peptide (GLP)-1 agonists weight loss drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The glucagon-like peptide (GLP)-1 agonists weight loss drugs market consists of sales of products such as dulaglutide (trulicity), exenatide (byetta, bydureon), and lixisenatide (adlyxin). Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on glucagon-like peptide (glp)-1 agonists weight loss drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for glucagon-like peptide (glp)-1 agonists weight loss drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The glucagon-like peptide (glp)-1 agonists weight loss drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drugs: Semaglutide; Liraglutide; Tirzepatide; Other Drugs
• 2) By Route of Administration: Parenteral; Oral
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Other Pharmacies
• Subsegments:
• 1) By Semaglutide: Ozempic; Wegovy; Rybelsus
• 2) By Liraglutide: Saxenda; Victoza
• 3) By Tirzepatide: Mounjaro; Zepbound
• 4) By Other Drugs: Exenatide; Dulaglutide; Albiglutide; Efpeglenatide
• Companies Mentioned: Pfizer Inc.; Roche Holding AG; Merck & Co. Inc; Amgen Inc.; Eli Lilly and Company
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Characteristics

3. Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Trends And Strategies

4. Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Growth Rate Analysis
• 5.4. Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Total Addressable Market (TAM)

6. Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Segmentation

• 6.1. Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Semaglutide
• Liraglutide
• Tirzepatide
• Other Drugs
• 6.2. Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Parenteral
• Oral
• 6.3. Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Other Pharmacies
• 6.4. Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Sub-Segmentation Of Semaglutide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ozempic
• Wegovy
• Rybelsus
• 6.5. Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Sub-Segmentation Of Liraglutide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Saxenda
• Victoza
• 6.6. Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Sub-Segmentation Of Tirzepatide, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Mounjaro
• Zepbound
• 6.7. Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Sub-Segmentation Of Other Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Exenatide
• Dulaglutide
• Albiglutide
• Efpeglenatide

7. Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Regional And Country Analysis

• 7.1. Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market

• 8.1. Asia-Pacific Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market

• 9.1. China Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Overview
• 9.2. China Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market

• 10.1. India Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market

• 11.1. Japan Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Overview
• 11.2. Japan Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market

• 12.1. Australia Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market

• 13.1. Indonesia Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market

• 14.1. South Korea Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Overview
• 14.2. South Korea Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market

• 15.1. Western Europe Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Overview
• 15.2. Western Europe Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market

• 16.1. UK Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market

• 17.1. Germany Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market

• 18.1. France Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market

• 19.1. Italy Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market

• 20.1. Spain Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market

• 21.1. Eastern Europe Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Overview
• 21.2. Eastern Europe Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market

• 22.1. Russia Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market

• 23.1. North America Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Overview
• 23.2. North America Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market

• 24.1. USA Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Overview
• 24.2. USA Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market

• 25.1. Canada Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Overview
• 25.2. Canada Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market

• 26.1. South America Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Overview
• 26.2. South America Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market

• 27.1. Brazil Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market

• 28.1. Middle East Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Overview
• 28.2. Middle East Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market

• 29.1. Africa Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Overview
• 29.2. Africa Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Drugs, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Competitive Landscape And Company Profiles

• 30.1. Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Competitive Landscape
• 30.2. Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis

31. Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Other Major And Innovative Companies

• 31.1. Novo Nordisk A/S
• 31.2. Teva Pharmaceutical Industries Ltd
• 31.3. Boehringer Ingelheim
• 31.4. Jiangsu Hengrui Medicine Co. Ltd
• 31.5. BioAge Labs
• 31.6. Hanmi Pharmaceutical
• 31.7. Innovent Biologics Inc.
• 31.8. Viking Therapeutics Inc.
• 31.9. Structure Therapeutics Inc.
• 31.10. Zealand Pharma A/S
• 31.11. Regor Therapeutics Inc.
• 31.12. I-Mab Biopharma (Shanghai) Co. Ltd.
• 31.13. Altimmune Inc.
• 31.14. TheracosBio LLC.
• 31.15. Oramed Pharmaceuticals

32. Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market

34. Recent Developments In The Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market

35. Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer